|
|
Anadrol 50 steroid :
This is an oral, methylated (17-alpha-alkylated) steroid that is both highly androgenic as well as highly anabolic. Some novice users report weight gains of up to a pound per day fpor the first 3 weeks of administration, as well as incredible strength gains. Neither is uncommon among first-time steroid users, and this type of weight gain makes Anadrol one of the most highly coveted drugs for off season mass-building cycles. Aggressiveness often increases dramatically on this compound, and that may be due to the elevation in androgen levels it provides, it's effects on the central nervous system, and it being derived from DHT (Dihydrotestosterone), which anecdotally seems to make athletes much more agressive. This last effect is often seen by the media as a negative side effect, but in a hard training (and emotionally stable) athlete, this aggressiveness often manifests itself as a stronger drive in the gym and results in more strength gained, and ultimately, more weight. Unfortunately, users of this drug also experience the negative aspects of DHT which can include excessive water retention, acne, and hairloss.
Anadrol 50 tablets by British Dragon
Many people consider Anadrol a dangerous compound, but this isn't necessarily so. Anadrol was originally produced in a whopping 50mg pill, so you don't need to take many of them to get a very high dose of Oxymetholone (the drug in Anadrol). Compare this dose to Anavar which is produced in a 2.5mg pill, or Dianabol which was produced in a 5mg pill, and you'll see why Anadrol has such a reputation for being powerful. One tab is has as many milligrams as 20 of the original Anavar tabs or 20 of the original Dianabol tabs! On a milligram for milligram basis, Anadrol is no more dangerous than most oral steroids out there. You just have to remember that you get 50mgs in each tablet, and adjust your dose accordingly. Occasionally people using Anadrol get flu-like-symptoms or a headache. I personally get both, but the headache is much worse (it is probably from my bloodpressure elevating quickly). Alot of the horror stories you hear about steroids is from people abusing this one in particulat. Chris Duffy ( a now retired IFBB professional) claimed to use ten of them every day. It's no wonder that it has been linked to prostate and liver cancer, liver disease, thyroid dysfunction, leukemia, and heart disorders, and even hepatic comas. Again, this is a powerful drug, and not to be taken lightly, but is no more dangerous than many others. It will also raise your hematocrit, and commesurately your blood pressure. to where clotting time may become an issue. Since Anadrol is derived from DHT, it can cause issues in DHT-sensitivce target tissure like the scalp, prostate, and sebaceous glands. It can also cause suppression of the Hypothalamic-Pituitary-Testicular-Axis, resulting in a low sperm count, and a lowering of Leutenizing hormone, which is what signals your testes to secrete testosterone. Anadrol therapy, therefore, will lower your testosterone levels.
Women generally steer clear of Anadrol, because of it's possible virilizing effects, including clitoral enlargement, facial hair growth, deeper voice, and missed periods..
Oxymetholone is infamous for negatively effecting liver function and increasing markers of that such as SGPT and SGOT enzymes (and others) which are all hepatic indicators (indicators of liver dysfunction). Jaundice (a yellowing of the whites of the eyes and finger nails) can even occur from extended Anadrol use. As previously stated, Anadrol is a derivative of DHT, which is itself a 5-alpha-reduced version of testosterone. Some androl users have reported gyno from its use but this is unlikely to be a result of anadrol (which doesn't convert to estrogen, nor DHT, nor can it stimulate the progesterone receptor). Users of Anadrol who experience gynocomastia (the of breast tissue by males) have probably developed this condition as a result of the concurrent use of another steroid along with their Anadrol. Oxymetholone also causes edema (water retention) which could possibly be due to enhanced retention, which often causes a smoothe appearance to muscles.
Andarol'is medical use is (as with most steroids) to treat low red blood cell production, which often manifests itself as aenemia. Therefore, during administration of Anadrol, red blood cell count is increased greatly. For the hard-training athlete, this is a great benefit bnecause it meant that there is more oxygen transported to the muscles, resulting in both an incredible muscle pump as well as increased ability to do multiple sets with very heavy weights. The time needed between sets, and ability to do more sets per workout are both increased, and a reduced need for off-days from the gym is often seen as well. This increased work capacity contributes to the athlete being able to do a great deal more productive weight training sessions per cycle, and this of course contributes to their gains immeasurably.
Advanced bodybuilders and power lifters have reported excellent results with 50-200 mg per day, taken in divided doses. It's very often the drug of choice for athletes attempting to move up a weight class in bodybuilding or powerlifting. Although myself and many others have used Anadrol alone, it's not very common to do so, and it's generally stacked with something like Testosterone, and Deca Durabolin or Equipoise. By stacking it with highly anabolic compounds like them, more high quality gains are generally seen, and less of the watery/bloated look is experienced.
Reported Characteristics
Pharmaceutical Name:Oxymetholone
Chemical name:17-beta-hydroxy-2-hydroxymethylene-17 alpha-methyl-5 alpha-androstan-3-one
Cutting/Bulking:Bulking
Anabolic Rating:320
Active - Life: Less than 16 hours
Drug Class: Highly Androgenic / Anabolic Steroid (Oral)
Average Reported Dosage: Men 50-200 mg daily.
Acne: Yes
Water Retention: Extreme
High Blood Pressure: Yes
Liver Toxic: High
DHT Conversions: DHT-Derived
Decreases HPTA Function: Yes
Aromatization: No
Average Price: Up to $3/tab
TRADE NAMES
ANAPOLON 100 100mg tabs
ANAPOLON 50
ANADROL-50 50 MG TABS
ANAPOLON 5, 50 MG TABS
HEMOGENIN 50 MG TABS
SYNASTERON 50 MG TABS
OXYMETHOLONE USP XXII 50 MG TABS
|
|
| Catalina Marketing Hires Johnson & Johnson Executive to Lead Health Care Services DivisionST. PETERSBURG, FL. March 9, 2010– Catalina Marketing
Corporation, the global leader in precision marketing and
shopper-driven media, today announced the appointment of Renee
Selman as President of its health care division, Catalina...


GSK CEO Andrew Witty Dedicates albendazole Facility in Nashik to WHO?s Global Programme to Eliminate LFLONDON, March 8, 2010--GlaxoSmithKline (GSK) CEO Andrew
Witty today dedicated a new production facility at its Nashik site
in India to the manufacture of albendazole, part of a combination
treatment used within the World Health...


Cardiff University and Merck Serono Launch International Survey For Couples Trying To Conceive• Largest study aimed at understanding the fertility
decision-making process of today’s couples trying to conceive
• Survey available in twelve languages on www.startingfamilies.com
Mumbai, India, March 9, 2010 – Merck Serono, a...


Exelixis Announces Restructuring- Aligning Resources with Late-Stage Compounds XL184,
XL147 and XL765 -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2010 -
Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a
consequence of its continued strategy to focus...


Nabi Closes License Deal With GlaxosmithklineFrom Associated Press (March 8, 2010)
ROCKVILLE, Md. -- Nabi Pharmaceuticals said Monday it closed an
option and license agreement for the smoking vaccine candidate
NicVAx with GlaxoSmithKline.
The deal is potentially worth more than $500 million,...


Mylan Rebukes and Cites Flaws in Bayer-Sponsored Mylan-Nifedipine Extended Release Bioequivalence Study in CanadaTORONTO, March 9 /CNW Telbec/ - Mylan (Nasdaq: MYL) today
reported that it has identified multiple flaws within a purported
bioequivalence study sponsored by Bayer Inc. of Canada. The study
compared Bayer's antihypertensive Adalat(R) XL(R) tablets,...


Roche Suspends Arthritis Drug Study After DeathsFrom Associated Press (March 8,
2010)
BASEL, Switzerland -- Swiss
pharmaceutical company Roche Group
said Monday it has suspended a late-stage trial for a new
rheumatoid arthritis and lupus drug after several patients died
from...


Roche and Biogen Idec Decide to Suspend Ocrelizumab Treatment - Rheumatoid Arthritis Development Programme on HoldFuture of the Ocrelizumab RA clinical programme under
evaluation
Basel, Switzerland, March 8, 2010--Roche
and Biogen Idec announced
today their decision to suspend Ocrelizumab
treatment of patients in the Rheumatoid Arthritis
(RA)...


Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9RxCARLSBAD, Calif., March 8, 2010
/PRNewswire via COMTEX/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has
earned a $6 million milestone payment from
Bristol-Myers Squibb Company (NYSE: BMY)
related to the acceptance of...


XenoPort Restructures to Focus on Key ProgramsSANTA CLARA, Calif.--(BUSINESS WIRE)--Mar 5, 2010 - XenoPort,
Inc. (Nasdaq:XNPT) announced today a restructuring that includes an
overall reduction in its workforce of approximately 50%. The
restructuring is designed to focus the Company's resources...


La Jolla Pharmaceutical Announces Termination of Merger Agreement with Adamis PharmaceuticalsSAN DIEGO--(BUSINESS WIRE)--Mar 5, 2010 - La Jolla
Pharmaceutical Company (Pink Sheets: LJPC) today announced that La
Jolla and Adamis Pharmaceuticals Corporation (OTCBB: ADMP) have
agreed to terminate their merger agreement relating to the...


Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay
Enterprises, Inc. (OTC:CHYE) (BULLETIN BOARD: CHYE) is pleased to
announce today that the company has merged with DMI Life Sciences,
Inc to form Ampio Pharmaceuticals, Inc. Ampio...


Pfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9MPfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9M [The
Day, New London, Conn.]
From Day, The (New London, CT) (March 4, 2010)
Mar. 4--As Pfizer Inc. continues a series of layoffs that are
expected to total nearly 20,000 by the time its...


Pfizer, Bristol-Myers Say Clot Drug Meets GoalsFrom Associated Press (March 5, 2010)
NEW YORK -- Bristol-Myers Squibb Co. and Pfizer Inc. on Thursday
said their blood thinner apixaban was more effective than
Sanofi-Aventis’ Lovenox in a late stage clinical trial.
The study compared the...


Grassley Statement on GAO Report about FDA Office of Criminal InvestigationsM E M O R A N D U M
TO: Reporters and Editors
RE: FDA Criminal Division
DA: Thursday, March 4, 2010
Senator Chuck Grassley issued the comment below about a newly
released report of the Government Accountability Office regarding
the criminal division...


Abbott Executives To Chair Medical Device LobbyFrom Associated Press (March 4, 2010)
WASHINGTON -- The medical device industry’s chief advocacy
group, AdvaMed, said Thursday an Abbott Laboratories executive will
serve as its chairman.
James Mazzo is President of Abbott Medical Optics, a...


Unilife and sanofi-aventis Agree to Exclusivity List for Unifill Ready-to-Fill Syringe
LEWISBERRY, Pa., March 2 /PRNewswire-FirstCall/ -- Unilife
Corporation ("Unilife" or "Company") (NASDAQ:UNIS) , today announced that it has
agreed to a list of therapeutic drug classes ("Exclusivity List")
within which sanofi-aventis...


Merck Statement on Vioxx Judgment in AustraliaWHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Mar 5, 2010 - Today,
the Federal Court in Australia published its judgment in the
Peterson case. The Court found against MSD Australia on two claims
under Australian statutory provisions. The Court...


District Court Upholds FDA's Grant of 5-Year Market Exclusivity to VYVANSE(R)PHILADELPHIA, March 4, 2010/PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical
company, announces that the United States District Court for the
District of Columbia ("Court"), following extensive...


H. Lundbeck A/S (DK) - Fourth Quarter and Full Year Report 2009 - Lundbeck Delivers 22 Percent Revenue Growth for 2009 and Meets Financial Expectations for 2009COPENHAGEN, March 4, 2010--H. Lundbeck A/S
(Lundbeck) announces 2009 results, which meet financial forecasts
and continue to show growth in all regions. Full year revenue
was DKK 13,747 million and increased 22% at
constant exchange rates compared...


NICE Appraisal of azacitidine for Myelodysplastic SyndromesLONDON, March 4, 2010--The National Institute for Health and
Clinical Excellence (NICE) is currently appraising the use of
azacitidine (Vidaza, Celgene) for myelodysplastic syndromes. In the
final draft guidance, published today (4 March 2010), NICE...


Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment CommunityWell-Positioned to Deliver
in 2010 and On Track to Execute BioPharma Strategy
Provides 2013 Minimum
Non-GAAP EPS Guidance
Will Present In-Depth
Review of Robust, Differentiated Pipeline
NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 - During a meeting...


KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs
Judge Sentences St. Louis-Based Company to Pay $27.6 Million
in Fines, Restitution and Forfeitures
WASHINGTON, March 2 /PRNewswire-USNewswire/ -- Ethex
Corporation, a wholly owned subsidiary of St. Louis-based drug
manufacturer, KV...


Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' Crinone Progesterone Gel Product Line- Established, patient-preferred infertility treatment - -
Expands Watson's Women's Health brand product portfolio - - Preterm
birth clinical trials currently underway - - Company acquires 11.2
million shares of Columbia common stock -
MORRISTOWN,...


Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone FranchiseWatson to acquire rights to
CRINONE® and
PROCHIEVE® and 11.2 million shares of
common stock for upfront and milestone payments of up to $92.5
million plus royalties
Also announces contingent agreements to retire
debt
Investor conference call...


Danish Lundbeck to Launch Two Depression Drugs in Phase IIIFrom Nordic Business Report (March 3, 2010)
3 March 2010 - Danish pharma company H Lundbeck
A/S (CPH: LUN) and its R&D partner Japanese
TakedaPharmaceutical Company Ltd (TYO:
4502) said today they will start pivotal clinical phase III...


Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain MedicinePRINCETON, N.J. & IRVINE, Calif.--(BUSINESS WIRE)--Mar 3,
2010 - Bristol-Myers Squibb Company (NYSE:
BMY) and Allergan
, Inc. (NYSE: AGN) today announced a global
agreement for the development and commercialization of
AGN-209323, a Phase...


Lundbeck and Takeda Finalize Plans to Initiate Phase III Pivotal Clinical Trials with Lu AA21004 and Lu AA24530OSAKA, March 3, 2010--H. Lundbeck A/S (Lundbeck) and Takeda
Pharmaceutical Company Limited (Takeda) today jointly announced the
plans for the additional clinical phase III studies on Lu AA21004
and phase III studies on Lu AA24530 in patients with...


Teva Announces Favorable Court Ruling in Generic Hyzaar and Cozaar LitigationJERUSALEM--(BUSINESS WIRE)--Mar 2, 2010 - Teva Pharmaceutical
Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Court
of Appeals for the District of Columbia Circuit has ruled in Teva's
favor by overturning a July 31, 2009, district court...


FDA Grants Final Approval For Generic FlomaxFrom Associated Press (March 2, 2010)
HAYWARD, Calif. -- Drugmaker Impax Laboratories Inc. said
Tuesday the Food and Drug Administration gave final approval to its
generic version of the enlarged prostate treatment Flomax.
Impax plans to start...


Dendreon Rises; FDA Says No Meeting on ProvengeFrom Associated Press (March 2, 2010)
WASHINGTON -- Shares of biotechnology company Dendreon Corp.
jumped Tuesday after federal regulators said they don’t plan
to hold a public meeting on the company’s prostate cancer
treatment, possibly...


Nabi Shareholders Approve Deal With GlaxoFrom Associated Press (March 2, 2010)
ROCKVILLE, Md. -- Nabi Biopharmaceuticals said Tuesday
shareholders approved its option and license agreement for the
smoking vaccine candidate NicVAx with GlaxoSmithKline.
More than 73 percent of Nabi’s...


Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as ChairmanNEW YORK--(BUSINESS WIRE)--Mar 2, 2010 -
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Lamberto Andreotti, 59, has been designated by the Board of
Directors to serve as the company's chief executive officer,
effective May 4, when...


Abbott and Enanta Announce Advancement of Hepatitis C CollaborationInitiation of Phase 2 Clinical Trial Investigating Three
Individual HCV Antivirals
ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2
/PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced
today the advancement of their...


Med Ad News' 21st Annual Manny Awards Will Honor Healthcare Advertising AgenciesMED AD NEWS' 21ST ANNUAL MANNY AWARDS WILL HONOR HEALTHCARE
ADVERTISING AGENCIES
NEWTOWN, Pa., March 2, 2010 - - On Thursday, April 22,
2010, Med Ad News magazine will host its 21st Annual Manny Awards
celebrating creative excellence in...


Baxter to Acquire All Outstanding Equity of ApaTech, Including ACTIFUSEDEERFIELD, Ill. and LONDON, U.K., March 1, 2010 – Baxter
International Inc. (NYSE:BAX), a global, diversified healthcare
company, and ApaTech, a private equity-backed, U.K.-based
orthobiologic products company, today announced a...


Watson Signs Agreement to Divest Equity Interest in ScinoPharmIntends to Use Proceeds to Support Business Development,
General Business Purposes
MORRISTOWN, N.J., March 1 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE:WPI) today announced that it signed an
agreement on February 26, 2010 to divest...


SuperGen Reports 2009 Fourth Quarter and Year-End Financial ResultsAchieves net income for quarter & year of $2.3 million
and $4.7 million, respectively
Ends year with over $100 million in cash, cash equivalents
& marketable securities
DUBLIN, Calif.--(BUSINESS WIRE)--Mar 1, 2010 - SuperGen...


OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma- Advises Stockholders to Take No Action at this Time
-
MELVILLE, N.Y.--(BUSINESS WIRE)--Mar 1, 2010 - OSI
Pharmaceuticals, Inc. (NASDAQ: OSIP) today confirmed that it has
received an unsolicited proposal from Astellas Pharma Inc.
("Astellas") to...


Stull, Stull & Brody Announces Investigation on Behalf of Shareholders of OSI Pharmaceuticals, Inc.NEW YORK--(BUSINESS WIRE)--Mar 1, 2010 - Attorney Advertising.
Notice is hereby given that Stull, Stull & Brody has commenced
an investigation on behalf of shareholders of OSI Pharmaceuticals,
Inc. (“OSI” or the...


|
|
| |
| |
|
|
|